Eli Lilly and Company

About

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, USA. The company focuses on developing innovative medicines for various health conditions, including diabetes, cancer, and autoimmune diseases.

Verified company data

Cash position

$9,353.4 million

Shares outstanding

895 million

Leadership

Jacob S. Van Naarden (Executive Vice President; President of Lilly Oncology and Head of Corporate Business Development, Jake oversees all aspects of oncology spanning discovery through commercial and has responsibility for Lilly’s corporate business development function. He joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. Jake has worked in various biotechnology investing, operational, and advisory capacities, including positions with HealthCor Management, Aisling Capital and Goldman Sachs.)

Verified data last updated: 2026-09-25

Recent filings

• Statement of changes in beneficial ownership of securities2026-09-22 · lly_2026-09-22_19-14-27.pdf→
• Statement of changes in beneficial ownership of securities2026-09-22 · lly_2026-09-22_19-12-51.pdf→
• Statement of changes in beneficial ownership of securities2026-09-22 · lly_2026-09-22_19-11-45.pdf→
• Statement of changes in beneficial ownership of securities2026-09-11 · lly_2026-09-11_19-16-07.pdf→
• Statement of changes in beneficial ownership of securities2026-09-04 · lly_2026-09-04_19-17-13.pdf→
• Statement of changes in beneficial ownership of securities2026-08-18 · lly_2026-08-18_19-20-56.pdf→
• Notice of proposed sale of securities pursuant to Rule 1442026-08-17 · lly_2026-08-17_20-06-30.pdf→
• Statement of changes in beneficial ownership of securities2026-08-11 · lly_2026-08-11_19-31-56.pdf→